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ABSTRACT
Objective: Lynestrenol, a progestin hormone derivative, can suppress the productions of endogenous estrogen and progesterone hormones (ovaries) 
to prevent ovulation. In this study, lynestrenol was included in various transfersomal gel preparations for its transdermal delivery into fat (F)-and 
non-fat (NF)-containing skin tissues.
Methods: Lynestrenol transfersome vesicles were prepared by encapsulating the drug in varied concentrations of phosphatidylcholine and Tween 
80 using lipid film hydration method. Transfersomes were produced in the form of gel preparations at a dose of 0.15 mg/week and evaluated for 
their particle size, percentage of entrapment efficiency, and particle polydispersity. We performed in vitro evaluations of the formulation variants F0 
(lynestrenol gel control) and F1 and F2 (lynestrenol transfersome gels) with variations in their phosphatidylcholine and Tween 80 content. We then 
performed an in vitro evaluation using the Franz diffusion cell (FDC) method for 12 h using all three formulations on F and NF-containing rat skin.
Results: The FDC results demonstrated that lynestrenol was deposited into fat tissue and increased concentrations of Tween 80 (edge activator) 
increased lynestrenol delivery into this tissue. In addition, the percentages of drug penetration from NF rat skin treated with F0, F1, and F2 gels were 
19.56%, 20.13%, and 20.56%, respectively, and those from F rat skin were 17.16%, 17.38%, and 17.50%, respectively.
Conclusion: In vitro evaluation using the FDC method indicates that transdermal drug delivery through to fat tissues using transfersomes is a 
promising method for lynestrenol delivery.
Keywords: Transfersomes, Lynestrenol, Franz diffusion cell.
INTRODUCTION
Oral contraceptive tablets have been used for more than 50 years, but 
user self-discipline is required as they must be consumed regularly at 
the same times each day [1]. Transdermal drug delivery systems have 
a number of advantages over oral pills, as they provide continuous 
administration of drug through the skin, which maintains constant 
plasma drug levels and avoids the peaks and troughs that are seen with 
oral drug administration [2].
The use of a transdermal system for contraception presents a number of 
clinical advantages over the conventional oral method. A once-weekly 
administration of a drug is more convenient for women compared with 
a once-daily administration and should also improve the overall efficacy 
by decreasing the degree to which it is dependent on user action [3].
From a pharmacokinetic perspective, transdermal delivery of 
contraceptive hormones eliminates variability in gastrointestinal (GI) 
absorption, and factors such as stomach pH, the stomach emptying rate, 
GI motility, and GI transit time [4]. The drug is delivered directly into 
the systemic circulation, which avoids hepatic first-pass metabolism 
and maintains constant circulating drug concentrations [5].
The fundamental challenge to transdermal drug delivery systems is 
crossing the barrier of the skin, which has a low permeability to foreign 
molecules due to the lipid-rich composition of the stratum corneum [6]. 
Solutes passing through the skin must move between cells and along 
the interfaces of extracellular lipid bilayers. As a result, sophisticated 
pharmacological and technical approaches are required to allow 
continuous drug delivery through the skin [7].
Lynestrenol is one of the hormones given by health workers to 
prospective reproductive patients [8]. It is able to effectively delay 
menstruation by inhibiting follicular maturation and preventing 
spikes in luteinizing hormone concentration so that the endometrium 
remains thin. The lynestrenol preparations that are currently available 
on the market are only in tablet form. A 0.5 mg dose is taken twice 
daily from the 5th day of the menstrual cycle. Orally administered 
lynestrenol undergoes first-pass metabolism, which results in 64% 
bioavailability of the drug compared with the amount consumed and 
a half-life of 5–6 h [9,10]. In this study, we examine the penetration of 
lynestrenol into the bloodstream using transdermal delivery to avoid 
the disadvantages of oral delivery.
MATERIALS AND METHODS
Materials
Lynestrenol was purchased from IPC (Pirumadara, India); Tween 80 and 
Phospholipon® 90G (Soya phosphatidylcholine ≥91%) were purchased 
from lipoid GmbH (Ludwigshafen, Germany); potassium dihydrogen 
phosphate monohydrate, sodium hydroxide, and dichloromethane 
were purchased from Merck (Darmstadt, Germany); methylparaben, 
propylparaben, glycerine, and propylene glycol were purchased from 
Dow Chemical (Jakarta, Indonesia); and hydroxypropyl methylcellulose 
(HPMC) K4M, sodium metabisulfite, aquadest, and ethanol (96%) 
were purchased from Merck (Darmstadt, Germany). Methanol and 




Vesicles were prepared using the thin-film hydration method. 
Different concentrations of the lipid Phospholipon® 90G (soya 
phosphatidylcholine) and the edge activator Tween 80 were employed 
for the formulation of the vesicles. The lipid, the edge activator, 
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and the drug (lynestrenol) were accurately weighed and dissolved 
in dichloromethane. This solution was evaporated using a rotary 
evaporator (Buchi R-100, Flawil, Switzerland) at 40°C and 850 mbar 
vacuum pressure. The thin film was maintained under a continuous flow 
of nitrogen and stored at 4°C for 24 h. The thin film obtained was then 
hydrated with phosphate-buffered saline (pH 7.4). The formulations 
used (with different concentrations of lipid and edge activator) are 
shown in Table 1 [11,12].
Determination of particle sizes, zeta potentials, and polydispersity 
indexes (PDIs)
The particle sizes, zeta potentials, and PDIs were measured for the F1 
and F2 transfersomes using the dynamic light scattering technique at 
25°C using the particle size system, (Zetasizer, Malvern, UK; Beckman 
Coulter, USA). The transfersomal colloidal dispersion was diluted with 
purified water before analysis [11,13].
Calculating the percentage of entrapment efficiency (EE%) of 
lynestrenol in transfersomes
Aliquots (1 ml) of the F1 and F2 transfersomes were separately 
centrifuged at 10,000 rpm for 1 h at 4°C to allow the separation 
of the non-entrapped drug. Next, 1 ml of 0.1% Triton X-100 was 
added and the mixture was centrifuged at 10,000 rpm for 1 h at 4°C 
to allow the separation of the entrapped drug. The supernatant 
was collected and 10 ml methanol was added. The mixture was 
analyzed chromatographically at 204 nm using a high-pressure liquid 
chromatography (HPLC) system (Shimadzu, Japan) [11,13]. The EE% of 
lynestrenol in the prepared transfersomes was calculated by applying 
the following equation:
%EE  






Preparation of lynestrenol gel and lynestrenol transfersome gels
In addition to gels prepared from of the F1 and F2 lynestrenol 
transfersomes, a control lynestrenol gel (F0) was also evaluated. 
Gels were formulated using 5% (w/v) HPMC as a gelling agent and 
approximately 0.15 mg of lynestrenol (F0) or 0.5 ml lynestrenol 
transfersomes (F1 and F2). First, HPMC was dispersed in distilled water 
and then mixed with F0, F1, or F2 while stirring. A mixture of 0.2% 
(w/v) methylparaben, 0.1% (w/v) propylparaben, 5% (w/v) glycerine, 
5% (w/v) propylene glycol, and 0.01% (w/v) sodium metabisulfite was 
subsequently added, and the mixture was stirred for 5 min at 500 rpm 
to adjust the pH to 6–7 and produce a proper gel consistency [12,13].
In vitro diffusion tests
Permeation studies were performed using a Franz diffusion cell 
apparatus with a 16 ml receptor compartment capacity and a diffusion 
area of 1.7 cm2. First, excised dorsal rat abdominal skin was mounted 
between the donor and receptor compartments of the diffusion cell 
with the stratum corneum layer facing into the donor compartment, 
while the dermis faced the receptor compartment. Phosphate-buffered 
saline (pH 7.4) was used as the receptor solution for permeability 
studies of all the prepared formulations (which were performed 
at a temperature of 37°C±2°C) for 12 h. Next, 0.5 g of gel prepared 
from each of the three formulations (F0, F1, and F2) were separately 
placed over fat-containing (F) and non-fat-containing (NF) areas of 
the stratum corneum facing the donor compartment. Samples (2 ml) 
were withdrawn at different intervals (1, 2, 3, 4, 5, 6, 8, 10, and 12 h) 
and analyzed for drug content using HPLC analysis. All experiments 
were performed in triplicate and the mean values were calculated. The 
percentage cumulative penetration per square centimeter of gel was 
plotted against time for each formulation [14,15].
RESULTS AND DISCUSSION
Particle sizes, zeta potentials, and PDIs
As shown in Table 2, the particle sizes of the F1 vesicles were smaller 
(443.90 nm) than the F2 vesicles (558.10 nm). This may be attributed 
to the fact that Tween 80 is a hydrophilic surfactant with a lower 
hydrophile-lipophile balance (HLB). Therefore, the transfersomes 
prepared with a small concentration of the surfactant Tween 80 (F1) 
have a smaller size compared with those prepared using a higher 
concentration (F2). The direct proportionality between vesicle size 
and the surfactant HLB can be explained by a reduction in surface free 
energy that takes place as a result of high hydrophobicity. The same 
explanation can be applied to the observation that a decrease in vesicle 
size occurs as the total lipid content increases.
As shown in Table 2, both of the formulations had negative zeta 
potential values: −23.81 mv for F1 and −21.86 mv for F2. It is highly 
likely that the negative zeta potential values of the transfersomes are 
largely due to the presence of ionic nitrogen atoms in the lynestrenol 
structure. The magnitudes of the zeta potentials in all the prepared 
formulations are sufficiently high to prevent their coagulation and to 
provide vesicle stability.
Size distribution is another highly important parameter that is 
expressed by a dimensionless value called the PDI. This parameter 
is a measure of particle homogeneity and varies from 0.0 to 1.0. The 
closer the PDI value is to zero, the more homogenous the vesicles will 
be. All the formulations showed good uniformity in vesicle size, as 
the PDI of F1 and F2 was measured as 0.550 and 0.441, respectively. 
This indicates that the vesicles were of a homogenous size and 
distribution, and suggested they were more uniform with a higher 
physical stability.
To summarize, two vesicle formulations (F1 and F2) with different 
concentrations of lipid (phospholipid) and edge activator (Tween 
80) were investigated. Table 2 shows their measured particle sizes, 
zeta potentials, and PDIs. Our EE experiments indicated that the F2 
formulation exhibited a higher EE (60.76%) than the F1 formulation 
(56.87%). F1 contained a greater concentration of soya phospholipid 
and a lower concentration of Tween 80 than F2. This suggests that 
the larger F2 particle size has more space for the entrapment of 
drugs.
In vitro diffusion test and deposition
The cumulative percentage of drug penetration into the receptor 
compartment fluid (transdermal amount) from the skin after 12 h 
of lynestrenol treatment using gels prepared using the formulations 
F0, F1, and F2 is presented in Fig. 1. These indicated that lynestrenol 
was deposited in the skin containing F than in that containing NF. 
A significantly higher lynestrenol penetration was obtained from the 
control lynestrenol gel (F0) than from the transfersomal lynestrenol 
gels (F1 and F2). The penetrated values of lynestrenol from NF skin 
were 19.56%, 20.13%, and 20.56% for F0-, F1-, and F2-delivered 
lynestrenol, respectively, and 17.16%, 17.38, and 17.50% for F0-, 






Lynestrenol 300 mg 300 mg
Phospholipon 90G 9 8
Tween 80 1 2
Phosphate buffer (pH 7.4) Add 50 ml Add 50 ml
Table 2: Transfersome characterization










F1 56.87 443.90 −23.80 0.550
F2 60.76 558.10 −21.86 0.441
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F1-, and F2-delivered lynestrenol, respectively, from NF skin after 
a 12-h penetrated. The higher lynestrenol penetration from the 
transfersomal gels could be attributed to the nature due to these 
formulations because the drug was present in nanosized lipid 
vesicles.
Furthermore, the addition of different surfactant molecules (e.g., Span 
80) in these formulations would facilitate the partitioning of the drug 
from the vesicles as they become associated with the phospholipid 
bilayer and therefore allow a higher drug penetrated from the vesicles.
We used different types of rat skin (F and NF) to study the in vitro 
penetration of lynestrenol (Fig. 1). Lynestrenol was deposited into F 
skin, presumably because transfer some carriers are known to cause 
drug accumulation in fatty tissues. Studies with F-containing skin, as 
opposed to NF skin, showed less penetration of lynestrenol; this was 
the case for lynestrenol deposited in fatty tissues from all the gel 
formulations. The differing lynestrenol permeation observed between 
the F1 and F2 formulations through skin is highly likely to be a result of 
their varied concentrations of soya phospholipid and Tween 80.
Increasing the concentration of Tween 80 (as in F2) increases the 
permeation of lynestrenols. Transfersomes containing Tween 80 have 
the structural flexibility to penetrate the skin and, as a result, the F2 
formulation causes a higher lynestrenol penetration compared with F1.
Based on our in vitro results, lynestrenol can be deposited into fat-
containing skin through both our formulations of transfersomal gels 
to allow a controlled dose of lynestrenol of 1 mg/day, over a single 
week (equivalent to 1 week of orally administered lynestrenol). The 
percentages of drug penetration from both the formulations (17.16% 
to 17.50% from fat-containing skin) indicate that a proportion of the 
drug is penetrated in 12 h while the rest accumulates in the skin.
CONCLUSION
In this study, we developed transdermal lynestrenol delivery systems 
using transfersomes. In addition, we demonstrated their capability to 
go through the skin barrier to deliver the drug.
Our in vitro studies using three different formulations showed that 
lynestrenol accumulated in fat and a deposition drug level could be 
detected after a 12-h application of the drug. Furthermore, in vitro 
studies showed a lower percentage penetration of lynestrenol deposited 
in F skin compared with NF skin.
Finally, based on our results, we can conclude that the formulated 
lynestrenol transfersomal gels do have potential for the efficient 
transdermal delivery of lynestrenol as they enable a significantly 
higher amount of lynestrenol to be permeated through excised rat skin 
compared with control (non-transfersomal) lynestrenol gels, which is 
concomitant with a higher flux and permeability coefficient.
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Fig. 1: Penetration profile of lynestrenol from formulations. 
F0: Lynestrenol gel, F1: Gel prepared from lynestrenol-containing 
transfersomes of formulation 1, F2: Gel prepared from 
lynestrenol-containing transfersomes of formulation 2. F: Rat 
skin with fat, NF: Rat skin without fat
